Can a drug help keep lung cancer from returning after surgery?

Imagine you've just had surgery to remove early-stage lung cancer. The operation went well, but now you're left with a nagging fear: what if it comes back? That's the question a large, late-stage trial tried to answer. It tested whether giving the immunotherapy drug pembrolizumab after surgery could help keep the cancer at bay longer than a placebo in over 1,100 patients. The trial followed patients for more than seven years, looking specifically at whether the drug delayed or prevented the cancer's return. It's important to note that the detailed results—like how much of a difference the drug made, or its side effects—haven't been shared publicly yet. The study was run by the company that makes the drug, which is standard practice but means we're waiting for their full report to understand what the data really shows.